You are here: Home » PTI Stories » National » News
Business Standard

Lupin gets USFDA nod to market antibacterial capsules

Press Trust of India  |  New Delhi 

Drug firm today said it has received final approval from the US health regulator to market its antibacterial capsules used for treating

The approval from the Food and Drug Administration (USFDA) is to market the capsules in the strengths of 50 mg and 100 mg, said in a statement.

The product is a generic version of Alvogen Malta Operations Ltd's Macrodantin capsules in the same strengths, it added.

The capsules are indicated for the treatment of caused by certain bacteria, said.

As per the IQVIA MAT April 2018 data capsules USP 50 mg and 100 mg had annual sales of around USD 27 million in the US, it added.

Shares of Lupin were toady trading at Rs 899.15 per scrip on BSE, down 0.22 per cent from its previous close.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Thu, July 12 2018. 13:40 IST